logo 600X600.png
Multiple System Atrophy (MSA) Market is expected to reach US$ 202.3 Million by 2031, Report by CoherentMI
14 oct. 2024 11h03 HE | CMI
Burlingame, Oct. 14, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Multiple System Atrophy (MSA) Market is estimated to value at US$ 148.1 Million in the year 2024, and is...
Alterity.png
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17 juil. 2024 07h35 HE | ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers...
Alterity.png
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17 juil. 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...
Alterity.png
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
29 mai 2024 19h21 HE | ALTERITY THERAPEUTICS LIMITED
- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May ...
Alterity.png
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
08 mai 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
 - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
Alterity.png
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
30 avr. 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...
Alterity.png
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17 avr. 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Alterity.png
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
10 avr. 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity.png
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
26 mars 2024 10h25 HE | ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company...
Alterity.png
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20 févr. 2024 10h25 HE | ALTERITY THERAPEUTICS LIMITED
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...